Krazati 200 MG tablet 180S
Ended Awarded Last action
- Contract number
- SPE2DR26FM2AY
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,310
Award facts
- Contract value 100% obligated
- $13,309.58 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,309.58 to Amerisourcebergen Drug Corp for the supply of Krazati 200 mg tablets (180-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of January 30, 2026, and was awarded on January 8, 2026. The awardee, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal healthcare systems, particularly military and veteran populations. This delivery order is executed under Amerisourcebergen Drug Corp's parent company Cencora, Inc. (doing business as Amerisourcebergen), which holds a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 2026, serving as the comprehensive vehicle for pharmaceutical supply across multiple therapeutic domains.
Amerisourcebergen Drug Corp maintains an extensive portfolio of federal medical procurement contracts with the DLA, demonstrating consistent capability to fulfill competitive federal requirements for both brand-name and generic medications across multiple therapeutic areas including oncology, diabetes management, pain control, and specialized medical supplies. The firm fixed-price structure and non-set-aside designation reflect the company's competitive positioning within the federal pharmaceutical supply market. This delivery order supports DLA's mission to provide critical pharmaceutical commodities to military treatment facilities, veterans' healthcare programs, and other federal medical institutions globally.
Quick answers
Who was awarded contract SPE2DR26FM2AY?
SPE2DR26FM2AY was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FM2AY worth?
The government has obligated $13,310 on SPE2DR26FM2AY.
Is contract SPE2DR26FM2AY an order under another contract?
Yes. SPE2DR26FM2AY is a delivery order under SPE2DR25D3501, an indefinite delivery contract.
Was contract SPE2DR26FM2AY competed?
The extent of competition for SPE2DR26FM2AY was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award